Bavarian Nordic A/S propose changes in Board of Directors
At Bavarian Nordic's Annual General Meeting 29 April 2008 the Board
of Directors will propose the election of managing director, M.S.,
M.D. Claus Bræstrup and President and CEO Gerard van Odijk, MD.
Managing Director Eigil Bjerl Nielsen will resign from the Board of
Directors, which he has been a member of since the founding of
Bavarian Nordic A/S in 1994. Following an approval at the Annual
General Meeting the Board of Directors will thereafter consist of:
Managing Director, Asger Aamund (Chairman)
Managing Director, Claus Bræstrup
Managing Director, Erling Johansen
President and CEO Gerard van Odijk
President and CEO Flemming Pedersen
As former President and CEO of H. Lundbeck A/S, Managing Director
Dr. Claus Bræstrup is publicly well-known in Denmark and
Internationally. Claus Bræstrup has a degree of Doctorate of Medicine
from the University of Copenhagen, where he also for a period was
Professor in Neuroscience. Claus Bræstrup is a Member of the Board at
the University of Copenhagen, LifeCycle Pharma (Chairman), Santaris
Pharma and he is also a member of the Danish National Advanced
Technology Foundation.
After some years as scientist at the Danish Ferrosan Group, Claus
Bræstrup has held a number of prominent top positions within Danish
and International pharmaceutical Industries (Novo Nordisk, Schering,
Lundbeck).
Claus Bræstrup is a writer and co-author of 125 scientific
publications.
Gerard van Odijk is a Dutch citizen and educated as MD at the
University of Utrecht. Gerard van Odijk, who is born in 1957, is
today President and CEO of Teva Pharmaceutical Europe B.V. With its
Headquarters in Israel Teva Pharmaceutical Industries has within a
short number of years grown into a global Pharmaceutical company with
26,000 employees and production facilities in Israel, North America,
Europe and Latin America.
In 2006 the turnover of The Teva Group amounted to approx. USD 8.5
Bn.
Gerard van Odijks International executive career has led to a variety
of senior positions in Glaxosmithkline (GSK). The last position held
was Area Director of Northern Europe. Dr. Van Odijk joined Teva
Pharmaceutical Europe B.V. as President and CEO in 2006.
Kvistgård, 14 April 2008
Asger Aamund
Chairman
Contact: Asger Aamund, Chairman | +45 33 26 83 83/+45 40 78
19 11
